1/15
07:47 am
vrax
Virax Biolabs Group (NASDAQ:VRAX) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
Virax Biolabs Group (NASDAQ:VRAX) was upgraded by analysts at Zacks Research to a "hold" rating.
1/13
04:06 am
vrax
Virax Biolabs Group (NASDAQ:VRAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Virax Biolabs Group (NASDAQ:VRAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
12:46 pm
vrax
Virax Biolabs Group (NASDAQ:VRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $3.00.
Medium
Report
Virax Biolabs Group (NASDAQ:VRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $3.00.
12/4
04:50 pm
vrax
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement [Yahoo! Finance]
Low
Report
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement [Yahoo! Finance]
12/4
04:05 pm
vrax
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Low
Report
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
12/3
03:26 pm
vrax
Virax Biolabs Group Limited Announces $5 Million Private Placement [Yahoo! Finance]
High
Report
Virax Biolabs Group Limited Announces $5 Million Private Placement [Yahoo! Finance]
12/3
01:53 pm
vrax
Virax Biolabs Group Limited Announces $5 Million Private Placement
Medium
Report
Virax Biolabs Group Limited Announces $5 Million Private Placement
12/3
07:34 am
vrax
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
High
Report
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
11/3
08:29 am
vrax
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Medium
Report
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes